Golden has been acquired by ComplyAdvantage.Read about it here ⟶

Clinical Studies Sponsored by Bluebird Bio

Clinical Studies Sponsored by Bluebird Bio

Clinical Studies Sponsored by University of Kansas

Clinical Studies Sponsored by BioCryst Pharmaceuticals

Clinical Studies Sponsored by Chinese Academy of Sciences

List of companies in Delphi Digital's investment portfolio

List of SBIR/STTR awards granted to Fluxion Biosciences

Clinical Studies where

Trial Sponsor

is

	Name	Description	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
	‌ A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel		NCT06224413		February 15, 2024	December 30, 2047	Observational
	‌ A Study of Participants With β-Thalassemia Treated With Betibeglogene Autotemcel		NCT06271512		January 23, 2024	2043	Observational
	‌ A Study Evaluating the Safety and Efficacy of bb1111 in Severe Sickle Cell Disease		NCT02140554		2014	2024	Interventional
	‌ A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants		NCT01745120		2013	February 21, 2018	Interventional
	‌ Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)		NCT02204904		2015	December 6, 2019	Observational
	‌ Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product		NCT02698579		January 22, 2016	2037	Observational
	‌ A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease		NCT04293185		February 14, 2020	2027	Interventional
	‌ A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia		NCT03207009		June 8, 2017	November 15, 2022	Interventional
	‌ A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)		NCT01896102		August 21, 2013	March 26, 2021	Interventional
	‌ Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy		NCT02633943		2014	2035	Observational
	‌ A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease		NCT02151526		June 7, 2013	February 26, 2019	Interventional

11 results

0 selected

11 results

0 selected